<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11859803</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.222</article-id><article-id pub-id-type="other">O0099</article-id><article-id pub-id-type="pii">S0924933824002220</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>Oral Communication</subject></subj-group></article-categories><title-group><article-title>An Umbrella Review of Effectiveness of Intravenous Ketamine in Treatment-Resistant Depression</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Klassen</surname><given-names>A. M.</given-names></name><xref rid="aff0329" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0083" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Baten</surname><given-names>C.</given-names></name><xref rid="aff0329" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shepherd</surname><given-names>J. H.</given-names></name><xref rid="aff0329" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zamora</surname><given-names>G.</given-names></name><xref rid="aff0329" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Johnson-Venegas</surname><given-names>E.</given-names></name><xref rid="aff0329" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Madugula</surname><given-names>S. S.</given-names></name><xref rid="aff0330" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Woo</surname><given-names>E.</given-names></name><xref rid="aff0329" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>J. A.</given-names></name><xref rid="aff0331" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sacchet</surname><given-names>M. D.</given-names></name><xref rid="aff0332" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hedges</surname><given-names>D. W.</given-names></name><xref rid="aff0333" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>C. H.</given-names></name><xref rid="aff0329" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff0329">
<sup>1</sup>Department of Psychology, <institution>California State University</institution>, <city>Fresno</city>, <country>Fresno</country></aff><aff id="aff0330">
<sup>2</sup>School of Medicine, <institution>Stanford University</institution>, <city>Stanford</city></aff><aff id="aff0331">
<sup>3</sup>Department of Psychology, <institution>Palo Alto University</institution>, <city>Palo Alto</city></aff><aff id="aff0332">
<sup>4</sup>Department of Psychiatry, Massachusetts General Hospital, <institution>Harvard Medical School</institution>, <city>Boston</city></aff><aff id="aff0333">
<sup>5</sup>Department of Psychology, <institution>Brigham Young University</institution>, Provo, <city>Provo</city>, <country>United States</country></aff><author-notes><corresp id="cor0083"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="197">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S86</fpage><lpage>S87</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824002220a.pdf"/><abstract><sec id="sec0495"><title>Introduction</title><p>Major depressive disorder (MDD) is a tremendous global disease burden and the leading cause of disability worldwide. Unfortunately, individuals diagnosed with MDD typically experience a delayed response to traditional antidepressants and many do not adequately respond to pharmacotherapy, even after multiple trials. The critical need for novel antidepressant treatments has led to a recent resurgence in the clinical application of psychedelics, and intravenous ketamine, which has been investigated as a rapid-acting treatment for treatment resistant depression (TRD) as well acute suicidal ideation and behavior. However, variations in the type and quality of experimental design as well as a range of treatment outcomes in clinical trials of ketamine make interpretation of this large body of literature challenging.</p></sec><sec id="sec0496"><title>Objectives</title><p>This umbrella review aims to advance our understanding of the effectiveness of intravenous ketamine as a pharmacotherapy for TRD by providing a systematic, quantitative, large-scale synthesis of the empirical literature.</p></sec><sec id="sec0497"><title>Methods</title><p>We performed a comprehensive PubMed search for peer-reviewed meta-analyses of primary studies of intravenous ketamine used in the treatment of TRD. Meta-analysis and primary studies were then screened by two independent coding teams according to pre-established inclusion criteria as well as PRISMA and METRICS guidelines. We then employed metaumbrella, a statistical package developed in R, to perform effect size calculations and conversions as well as statistical tests.</p></sec><sec id="sec0498"><title>Results</title><p>In a large-scale analysis of 1,182 participants across 51 primary studies, repeated-dose administration of intravenous ketamine demonstrated statistically significant effects (p&#x0003c;0.05) compared to placebo-controlled as well as other experimental conditions in patients with TRD, as measured by standardized clinician-administered and self-report depression symptom severity scales.</p></sec><sec id="sec0499"><title>Conclusions</title><p>This study provides large-scale, quantitative support for the effectiveness of intravenous, repeated-dose ketamine as a therapy for TRD and a report of the relative effectiveness of several treatment parameters across a large and rapidly growing literature. Future investigations should use similar analytic tools to examine evidence-stratified conditions and the comparative effectiveness of other routes of administration and treatment schedules as well as the moderating influence of other clinical and demographic variables on the effectiveness of ketamine on TRD and suicidal ideation and behavior.</p></sec><sec id="sec0500"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>